New hope for lupus skin flares? phase 3 trial launches

NCT ID NCT07332481

Recruiting now Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated May 21, 2026 · Updated 20 times

Summary

This study tests an experimental drug called enpatoran for people with lupus that causes active skin rashes or sores. About 202 adults with lupus skin disease will receive either enpatoran or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly reduce skin symptoms and improve overall disease control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Allen Arthritis
RECRUITING

Allen, Texas, 75013, United States
Arthritis and Rheumatology Research Institute PLLC
RECRUITING

Allen, Texas, 75013, United States
Dermatology Research Associates - 300204025
RECRUITING

Los Angeles, California, 90045, United States
Emory University School of Medicine
RECRUITING

Atlanta, Georgia, 30303, United States
Revival Research Institute, LLC
RECRUITING

Troy, Michigan, 48084, United States

Conditions

Explore the condition pages connected to this study.

CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)